Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 2(2)
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07297654Phase 2Not Yet Recruiting

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment

Role: collaborator

NCT06124833Recruiting

Omics-driven Research on the Gut-Oral Microbiome, Metabolome, Lifestyle, and Clinical Integration in Korean Inflammatory Bowel Disease

Role: collaborator

NCT05992220Phase 2Recruiting

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

Role: collaborator

NCT01258673Phase 3Completed

A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy

Role: collaborator

NCT01124266Phase 4Completed

Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy

Role: collaborator

All 5 trials loaded